과제정보
This work was supported by grants from the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (grant no. NRF-2022R1A2C109214511 to I.-K.C.) and the DGIST Start-up Fund Program of the Ministry of Science and ICT (grant no. 2023010020 to I.-K.C.).
참고문헌
- Zhou L, Chong MM and Littman DR (2009) Plasticity of CD4+ T cell lineage differentiation. Immunity 30, 646-655 https://doi.org/10.1016/j.immuni.2009.05.001
- Zhu J, Yamane H and Paul WE (2010) Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 28, 445-489 https://doi.org/10.1146/annurev-immunol-030409-101212
- Zappasodi R, Merghoub T and Wolchok JD (2018) Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell 33, 581-598 https://doi.org/10.1016/j.ccell.2018.03.005
- Barrett DM, Singh N, Porter DL, Grupp SA and June CH (2014) Chimeric antigen receptor therapy for cancer. Annu Rev Med 65, 333-347 https://doi.org/10.1146/annurev-med-060512-150254
- Ott PA, Hodi FS, Kaufman HL, Wigginton JM and Wolchok JD (2017) Combination immunotherapy: a road map. J Immunother Cancer 5, 16
- Johnson DB, Estrada MV, Salgado R et al (2016) Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun 7, 10582
- Rodig SJ, Gusenleitner D, Jackson DG et al (2018) MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med 10, eaar3342
- Johnson DB, Bordeaux J, Kim JY et al (2018) Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma. Clin Cancer Res 24, 5250-5260 https://doi.org/10.1158/1078-0432.CCR-18-0309
- Park IA, Hwang SH, Song IH et al (2017) Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. PLoS One 12, e0182786
- Loi S, Dushyanthen S, Beavis PA et al (2016) RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 22, 1499-1509 https://doi.org/10.1158/1078-0432.CCR-15-1125
- Michel S, Linnebacher M, Alcaniz J et al (2010) Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer 127, 889-898 https://doi.org/10.1002/ijc.25106
- Bustin SA, Li SR, Phillips S and Dorudi S (2001) Expression of HLA class II in colorectal cancer: evidence for enhanced immunogenicity of microsatellite-instability-positive tumours. Tumour Biol 22, 294-298 https://doi.org/10.1159/000050630
- Callahan MJ, Nagymanyoki Z, Bonome T et al (2008) Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res 14, 7667-7673 https://doi.org/10.1158/1078-0432.ccr-08-0479
- Turner TB, Meza-Perez S, Londono A et al (2017) Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. Oncotarget 8, 44159-44170 https://doi.org/10.18632/oncotarget.17395
- Younger AR, Amria S, Jeffrey WA et al (2008) HLA class II antigen presentation by prostate cancer cells. Prostate Cancer Prostatic Dis 11, 334-341 https://doi.org/10.1038/sj.pcan.4501021
- Roemer MGM, Redd RA, Cader FZ et al (2018) Major histocompatibility complex class ii and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma. J Clin Oncol 36, 942-950 https://doi.org/10.1200/JCO.2017.77.3994
- Soos JM, Krieger JI, Stuve O et al (2001) Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation. Glia 36, 391-405 https://doi.org/10.1002/glia.1125
- Yazawa T, Kamma H, Fujiwara M et al (1999) Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 187, 191-199 https://doi.org/10.1002/(SICI)1096-9896(199901)187:2<191::AID-PATH206>3.0.CO;2-3
- Quezada SA, Simpson TR, Peggs KS et al (2010) Tumorreactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207, 637-650 https://doi.org/10.1084/jem.20091918
- Xie Y, Akpinarli A, Maris C et al (2010) Naive tumorspecific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 207, 651-667 https://doi.org/10.1084/jem.20091921
- Hirschhorn-Cymerman D, Budhu S, Kitano S et al (2012) Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med 209, 2113-2126 https://doi.org/10.1084/jem.20120532
- Curran MA, Geiger TL, Montalvo W et al (2013) Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 210, 743-755 https://doi.org/10.1084/jem.20121190
- Kitano S, Tsuji T, Liu C et al (2013) Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res 1, 235-244 https://doi.org/10.1158/2326-6066.CIR-13-0068
- Puram SV, Tirosh I, Parikh AS et al (2017) Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611-1624 e1624
- Azizi E, Carr AJ, Plitas G et al (2018) Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293-1308 e1236
- Zhang Y, Chen H, Mo H et al (2021) Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 39, 1578-1593 e1578
- Guo X, Zhang Y, Zheng L et al (2018) Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med 24, 978-985 https://doi.org/10.1038/s41591-018-0045-3
- Zhang L, Yu X, Zheng L et al (2018) Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268-272 https://doi.org/10.1038/s41586-018-0694-x
- Zhang Q, He Y, Luo N et al (2019) Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell 179, 829-845 e820
- Zheng C, Zheng L, Yoo JK et al (2017) Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342-1356 e1316
- Oh DY, Kwek SS, Raju SS et al (2020) Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181, 1612-1625 e1613
- Tang XX, Shimada H and Ikegaki N (2021) Clinical relevance of CD4 cytotoxic T cells in high-risk neuroblastoma. Front Immunol 12, 650427
- Zhou Y, Yang D, Yang Q et al (2020) Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun 11, 6322
- Porakishvili N, Kardava L, Jewell AP et al (2004) Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica 89, 435-443
- Khanna R, Burrows SR, Thomson SA et al (1997) Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. J Immunol 158, 3619-3625 https://doi.org/10.4049/jimmunol.158.8.3619
- Cader FZ, Hu X, Goh WL et al (2020) A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med 26, 1468-1479 https://doi.org/10.1038/s41591-020-1006-1
- Cachot A, Bilous M, Liu YC et al (2021) Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci Adv 7, eabe3348
- Hu Z, Leet DE, Allesoe RL et al (2021) Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med 27, 515-525 https://doi.org/10.1038/s41591-020-01206-4
- Melenhorst JJ, Chen GM, Wang M et al (2022) Decadelong leukaemia remissions with persistence of CD4(+) CAR T cells. Nature 602, 503-509 https://doi.org/10.1038/s41586-021-04390-6
- Choi IK, Wang Z, Ke Q et al (2018) Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4(+) and CD8(+) T cell responses. Proc Natl Acad Sci U S A 115, E686-E695 https://doi.org/10.1073/pnas.1713607115
- Choi IK, Wang Z, Ke Q et al (2021) Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature 590, 157-162 https://doi.org/10.1038/s41586-020-03075-w
- Sledzinska A, Vila de Mucha M, Bergerhoff K et al (2020) Regulatory T cells restrain interleukin-2- and blimp-1-dependent acquisition of cytotoxic function by CD4(+) T cells. Immunity 52, 151-166 e156
- Takeuchi A, Badr Mel S, Miyauchi K et al (2016) CRTAM determines the CD4+ cytotoxic T lymphocyte lineage. J Exp Med 213, 123-138 https://doi.org/10.1084/jem.20150519
- Brown DM, Kamperschroer C, Dilzer AM, Roberts DM and Swain SL (2009) IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. Cell Immunol 257, 69-79 https://doi.org/10.1016/j.cellimm.2009.03.002
- Cruz-Guilloty F, Pipkin ME, Djuretic IM et al (2009) Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med 206, 51-59 https://doi.org/10.1084/jem.20081242
- Serroukh Y, Gu-Trantien C, Hooshiar Kashani B et al (2018) The transcription factors Runx3 and ThPOK crossregulate acquisition of cytotoxic function by human Th1 lymphocytes. Elife 7, e30496
- Lancki DW, Hsieh CS and Fitch FW (1991) Mechanisms of lysis by cytotoxic T lymphocyte clones. Lytic activity and gene expression in cloned antigen-specific CD4+ and CD8+ T lymphocytes. J Immunol 146, 3242-3249 https://doi.org/10.4049/jimmunol.146.9.3242
- Akhmetzyanova I, Zelinskyy G, Littwitz-Salomon E et al (2016) CD137 agonist therapy can reprogram regulatory T cells into cytotoxic CD4+ T cells with antitumor activity. J Immunol 196, 484-492 https://doi.org/10.4049/jimmunol.1403039
- Appay V, Zaunders JJ, Papagno L et al (2002) Characterization of CD4(+) CTLs ex vivo. J Immunol 168, 5954-5958 https://doi.org/10.4049/jimmunol.168.11.5954
- Takeuchi A and Saito T (2017) CD4 CTL, a cytotoxic subset of CD4(+) T cells, their differentiation and function. Front Immunol 8, 194
- Waight JD, Chand D, Dietrich S et al (2018) Selective fcgammar co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens. Cancer Cell 33, 1033-1047 e1035
- Braumuller H, Wieder T, Brenner E et al (2013) T-helper-1-cell cytokines drive cancer into senescence. Nature 494, 361-365 https://doi.org/10.1038/nature11824
- Kammertoens T, Friese C, Arina A et al (2017) Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression. Nature 545, 98-102 https://doi.org/10.1038/nature22311
- Corthay A, Skovseth DK, Lundin KU et al (2005) Primary antitumor immune response mediated by CD4+ T cells. Immunity 22, 371-383 https://doi.org/10.1016/j.immuni.2005.02.003
- Kennedy R and Celis E (2008) Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 222, 129-144 https://doi.org/10.1111/j.1600-065X.2008.00616.x
- Haabeth OAW, Hennig K, Fauskanger M, Loset GA, Bogen B and Tveita A (2020) CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages. Blood Adv 4, 2595-2605 https://doi.org/10.1182/bloodadvances.2020001434
- Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B and Mach B (1994) Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265, 106-109 https://doi.org/10.1126/science.8016643
- Neefjes J, Jongsma ML, Paul P and Bakke O (2011) Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11, 823-836 https://doi.org/10.1038/nri3084